Home » Cervical Cancer Diagnostic Test Market

Cervical Cancer Diagnostic Test Market By Diagnostic Test Type (PAP Tests, HPV Tests, Biopsy, Colposcopy, Cystoscopy) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 3798 | Report Format : PDF

Cervical Cancer Diagnostic Test Market to Exhibit Profitable Growth During the Forecast Period

The global cervical cancer diagnostic test market was growing significantly and was valued at US$ 8,779.2 million in 2017; it is expected to attain US$ XX million by 2026. The growing prevalence of cervical cancer worldwide, as well as a growing female population aged 25 to 60 years, are the major factors driving the global cervical cancer diagnostic test market. In addition, new technological progress in HPV testing and Pap (Papanicolaou) testing is generating major revenue in the developed markets. Also, favorable private and public initiatives in the medical sector across various developing countries, product expansion, and increasing lab tests with higher acceptance of instruments and kits will further assist in the overall cervical cancer diagnostic test market growth.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

The Pap test segment was leading the worldwide market in 2017. The Pap (Papanicolaou) test is a screening test that is generally used to determine cervical health. Enhanced Pap test screenings have made it simpler for doctors and specialists to discover cancerous cells. Digital screening, regularly called Focal Point or AutoPap, utilizes a computer to filter the sample for abnormal cells. The improvement in computer-guided cancer tests to minimize errors and improve precision is expected to drive the growth of the market. Pap tests give continuous comprehension of current cell development and demonstrate whether strange cell development is probably going to wind up malignant in the near term if left untreated. Furthermore, the HPV (Human Papillomavirus) test is utilized to recognize diseases with high-hazard HPV, the infection that causes cervical disease. Over 90% of cervical malignancies happen because of HPV infection, and they are analyzed through Pap smear screening and HPV testing. The two most well-known types of cervical cell tumors are adenocarcinoma and squamous cell carcinoma.

Various screening tests for females with symptoms of cervical cancer or abnormal Pap results include past medical history and physical examination, colposcopy, cervical biopsies, endocervical curettage (endocervical scraping), cone biopsy, loop electrosurgical procedure (LEEP, LLETZ), cold knife cone biopsy, and other imaging tests such as chest x-ray, computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and positron emission tomography (PET) scan.

Various external factors contribute to the expanding prevalence of cervical disease around the world. These include a rising number of female smokers, a huge number of patients experiencing HPV contamination, a developing obese population (age group 21–60 years), and expanding occurrences of unsafe sex, especially among youngsters. Cancer awareness programs and early diagnosis likewise contribute to the development of this market. Cervical cancer diagnostic tests, as well as advanced laboratory testing procedures, are driving up demand, particularly in the Asia Pacific and Europe.

Inaccurate Pap smear testing, low-grade vaccination, ineffectual medical service foundations and cancer institutes, less awareness about cervical malignancy, stringent government regulations, and a cheap and alternative approach toward cervical cancer diagnosis in developing nations are a few external factors that hinder the development of the worldwide cervical cancer diagnostic test market. New and advanced technology assessment in laboratory testing, an increasing population in developing nations such as India, China, Brazil, and others, and healthcare infrastructure improvements in rising economies are factors spurring revenue growth in this market.

Other prominent drivers include low immunity factors in women working in developing countries due to a deficiency in the right nutritional intake, an upsurge of human papillomavirus in females, higher usage of oral contraceptive pills by females, and having multiple sex partners with unsafe sex.

Market Synopsis

The Pap Test Type Segment is expected to register higher growth in the Developing Nations by the end of 2026.

In the past decade, various studies and research have shown that the regular history of corrective diagnostic testing has significantly affected the rate of cancer worldwide.

A Pap test, also known as a Pap smear, is the most widely recognized test for detecting early changes in cells that can lead to cervical cancer. It includes gathering a sample of cells from the cervix. A portion of the cells collected from the cervix during a Pap smear test may also be tested for human papillomavirus or HPV. Contamination with HPV is a risk factor for cervical tumors. Pap smear tests give an ongoing comprehension of current cell development and show whether abnormal cell development is probably going to become more cancerous in the near term if left untreated.

According to the American Cancer Society and the World Health Organization, top-quality screening with Pap and HPV tests has extraordinarily lessened mortality from cervical cancer. Since the introduction of Pap testing in the U.S. in the 1950s, cervical tumors, once the most common reason for deaths due to malignancy in females, now rank fourteenth, which denotes a 70 percent decrease over that time range. This decrease in mortality is the immediate consequence of Pap and HPV diagnostics that have expanded the detection of cervical cancer at the beginning of the diagnosis, lessening the general frequency of cervical cancer worldwide.

In April 2014, the U.S. FDA approved the utilization of a single HPV DNA test (the COBAS test, by Roche) as a first-line principal screening test for use only in females aged 25 years and older. This particular test identifies each of the HPV types, mainly 18 and 16, and gives collective marks for 12 supplementary risky HPV categories.

In Developing Economies, the rising prevalence of cervical cancer, combined with advanced diagnostic procedures, is gaining traction.

North America spearheaded the market in 2017 owing to the presence of established players and increasing incidences of cervical cancer in the U.S., as indicated by a report published by the American Cancer Society, in which around 4000 females died due to cervical cancer. As per the research study, the American Cancer Society’s projections for cervical cancer in the U.S. for 2018 are that around 13,000 fresh cases of cervical cancer will be diagnosed in females, and around 4,100 females will die from this disease. However, deaths from cervical cancer in the U.S. keep declining by around 2 percent a year. This decrease is largely due to the increased use of the Pap test to identify cervical variations and permit early treatment.

Expanding the number of techniques for cervical cancer diagnostic tests alongside rising approvals from the U.S. FDA is relied upon to drive the development of the worldwide cervical cancer diagnostic test market. The rising trend of HPV test procedures alone in the U.S. and Europe, along with increasing awareness for new computerized diagnostic tests and cervical cancer screening programs, is gaining momentum in the global market.

Moreover, Asia Pacific is relied upon to indicate fast development in the cervical cancer diagnostic test market, attributable to expanding R&D and approval of novel test kits and instruments in India and China. Furthermore, rising cervical cancer prevalence increased acceptance of international brands in developing countries, technology assessment with increased FDA approval for Pap and HPV testing, and a growing need for advanced diagnostic procedures such as colposcopy, cystoscopy, cone biopsy, and imaging tests, as well as increased awareness, are expected to drive the cervical cancer diagnostic tests market during the forecast period.

Market penetration for emerging players is difficult due to the dominance of established multinational players with strong product portfolios.

Major players in the cervical cancer diagnostic test market are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc., and others. These manufacturers are implementing growth strategies along with new technology assessments, approvals for new diagnostic kits and instruments for cancer, and partnerships with medical technology companies to increase economic benefits. Roche developed the CINtec PLUS automated cytology test in 2014 to remove unhealthy tissue from the cervix site prior to the growth of cancerous cells. Furthermore, Roche announced that Avastin, a combination of medicine and chemotherapy for treating patients with advanced cervical cancer, had received FDA approval in the United States.

Periods of History and Forecast

This study report includes an analysis for each segment from 2016 to 2026, with 2017 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2018 to 2026.

Report Scope by Segments

The cervical cancer diagnostic test market comprises current market trends and dynamics along with a quantitative analysis of the global market. The report elucidates thorough information about the global cervical cancer diagnostic test market by segmenting the market in terms of product, modality, end-user, and geography. This report will assist healthcare professionals and market participants in making decisions and strategizing market positions.

The current report also encompasses qualitative market assessment factors such as market trends, key market drivers, restraints, and opportunities that give a better understanding of the overall cervical cancer diagnostic test market. Furthermore, the report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths. Key industrial players profiled in the study report are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc., and others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key questions are answered in this report.

  • What are the current market trends and dynamics in the cervical cancer diagnostic test market, and what are the valuable opportunities for emerging players?
  • What is the market positioning of the major market players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which end-user holds a larger market share and why?
  • What is the impact of the high cost of screening tests on the cervical cancer diagnostic test market?
  • Are low- and middle-income economies investing in the cervical cancer diagnostic test market?
  • What are the market trends and dynamics in emerging markets such as Japan, Latin America, the Middle East, and Africa?

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global CCDT Market Portraiture
2.2. Global CCDT Market, By Diagnostic Test Type, 2017 (US$ Mn)
2.3. Global CCDT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Cervical Cancer Diagnostic Test (CCDT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Cervical Cancer Diagnostic Test: Future Trends
3.3. Current Scenario: Strategies Used for Drug Delivery Across BBB Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Cervical Cancer Diagnostic Test (CCDT) Market, by Diagnostic Test Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. PAP Tests
4.3. HPV Tests
4.4. Biopsy
4.4.1. Cone biopsy
4.4.2. Endocervical Curettage
4.4.3. Punch biopsy & Others
4.5. Colposcopy
4.6. Cystoscopy

Chapter 5. Global Cervical Cancer Diagnostic Test (CCDT) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America CCDT Market Analysis, 2016 – 2026
5.2.1. North America CCDT Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.2.2. North America CCDT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe CCDT Market Analysis, 2016 – 2026
5.3.1. Europe CCDT Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe CCDT Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific CCDT Market Analysis, 2016 – 2026
5.4.1. Asia Pacific CCDT Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific CCDT Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest of APAC
5.5. Latin America CCDT Market Analysis, 2016 – 2026
5.5.1. Latin America CCDT Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America CCDT Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) CCDT Market Analysis, 2016 – 2026
5.6.1. MEA CCDT Market, by Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA CCDT Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Hologic Corporation
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Becton, Dickinson and Company
6.3. Qiagen N.V.
6.4. Siemens Healthcare
6.5. Guided Therapeutics, Inc.
6.6. Ascon Medical Instruments Pvt Ltd
6.7. Hoffmann-La Roche
6.8. Cooper Surgical Inc.
6.9. Cardinal Health, Inc.
6.10. Beckman Coulter Inc.

List of Figures

FIG. 1 Global Cervical Cancer Diagnostic Test (CCDT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global CCDT Market Segmentation
FIG. 4 Global CCDT Market, by Diagnostic Test Type, 2017 (US$ Mn)
FIG. 5 Global CCDT Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Global Market Positioning of Key Cervical Cancer Diagnostic Test Manufacturers, 2017
FIG. 8 Global Pap Test Market for Cervical Cancer Diagnostic Test, 2016–2026 (US$ Mn)
FIG. 9 Global HPV Test Market for Cervical Cancer Diagnostic Test, 2016–2026 (US$ Mn)
FIG. 10 Global Biopsy Test Market for Cervical Cancer Diagnostic Test, 2016–2026 (US$ Mn)
FIG. 11 Global Colposcopy Market for Cervical Cancer Diagnostic Test, 2016–2026 (US$ Mn)
FIG. 12 Global Cystoscopy Market for Cervical Cancer Diagnostic Test, 2016–2026 (US$ Mn)
FIG. 13 U.S. CCDT Market, 2016–2026 (US$ Mn)
FIG. 14 Canada CCDT Market, 2016–2026 (US$ Mn)
FIG. 15 U.K. CCDT Market, 2016–2026 (US$ Mn)
FIG. 16 Germany CCDT Market, 2016–2026 (US$ Mn)
FIG. 17 Rest of Europe CCDT Market, 2016–2026 (US$ Mn)
FIG. 18 Japan CCDT Market, 2016–2026 (US$ Mn)
FIG. 19 China CCDT Market, 2016–2026 (US$ Mn)
FIG. 20 Rest of Asia Pacific CCDT Market, 2016–2026 (US$ Mn)
FIG. 21 Brazil CCDT Market, 2016–2026 (US$ Mn)
FIG. 22 Mexico CCDT Market, 2016–2026 (US$ Mn)
FIG. 23 Rest of Latin America CCDT Market, 2016–2026 (US$ Mn)
FIG. 24 GCC CCDT Market, 2016–2026 (US$ Mn)
FIG. 25 Rest of Middle East & Africa CCDT Market, 2016–2026 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Cervical Cancer Diagnostic Test (CCDT) Market
TABLE 2 Global CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 3 Global CCDT Market, by Geography, 2016–2026 (US$ Mn)
TABLE 4 North America CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 5 North America CCDT Market, by Country, 2016–2026 (US$ Mn)
TABLE 6 Europe CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 7 Europe CCDT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 8 Latin America CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 9 Latin America CCDT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 10 Asia Pacific CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 11 Asia Pacific CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 12 Asia Pacific CCDT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 13 Middle East & Africa CCDT Market, by Diagnostic Test Type, 2016–2026 (US$ Mn)
TABLE 14 Middle East & Africa CCDT Market, by Region, 2016–2026 (US$ Mn)
TABLE 15 Hologic Corporation.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 16 Becton, Dickinson and Company: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 17 Qiagen N.V.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 18 Siemens Healthcare: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 19 Guided Therapeutics Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 20 Ascon Medical Instruments Pvt Ltd: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 Hoffmann-La Roche.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 Cooper Surgical Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 Cardinal Health, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 Beckman Coulter Inc. Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)

Frequently Asked Questions

What is the size of Cervical Cancer Diagnostic Test Market?

The market for Cervical Cancer Diagnostic Test Market is expected to reach US$ XX Bn by 2026.

What is the Cervical Cancer Diagnostic Test Market CAGR?

The Cervical Cancer Diagnostic Test Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Cervical Cancer Diagnostic Test Market?

The report is forecasted from 2018-2026.

What is the base year considered for Cervical Cancer Diagnostic Test Market?

The base year of this report is 2017.

Who are the major players in this market?

Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt. Ltd., Hoffmann-La Roche, Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc. are some of the major players in the global market.

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Basal Cell Carcinoma (BCC) Treatment Market

Published:
Report ID: 32698

Paroxysmal Nocturnal Hemoglobinuria Market

Published:
Report ID: 8654

Reversible Airway Diseases Treatment Market

Published:
Report ID: 32531

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN